Skip to main content
main-content
Erschienen in: Endocrine 2/2020

24.04.2020 | Review

Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials

verfasst von: Panagiotis Anagnostis, Konstantina Vaitsi, Panagiota Kleitsioti, Chrysanthi Mantsiou, Konstantinos Pavlogiannis, Vasilios G. Athyros, Dimitri P. Mikhailidis, Dimitrios G. Goulis

Erschienen in: Endocrine | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Statins are the mainstay of treatment for patients with familial hypercholesterolaemia (FH). However, their efficacy and safety in children and adolescents with FH has not been well-documented. The purpose of this study was to systematically investigate and meta-analyze the best available evidence from randomized-controlled trials (RCTs) regarding the efficacy and safety of statins in this population.

Methods

A comprehensive search was conducted in PubMed, Scopus and Cochrane, up to 10 January 2020. Data were expressed as mean differences with 95% confidence intervals (CI). The I2 index was employed for heterogeneity.

Results

Ten RCTs were included in the qualitative and quantitative analysis (1191 patients, aged 13.3 ± 2.5 years). Compared with placebo, statins led to a mean relative reduction in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride and apolipoprotein B (apo-B) concentrations by −25.5% (95% CI −30.4%, −20.5%; I2 91%), −33.8% (95% CI −40.1%, −27.4%; I2 90%), −8.4% (95% CI −14.8%, −2.03%; I2 26%) and −28.8% (95% CI −33.9%, −23.6%; I2 83%), respectively. High-density lipoprotein cholesterol (HDL-C) was increased by 3.1% (95% CI 1.1%−5.2%; I2 0%). Statins were well-tolerated, with no significant differences in transaminase and creatine kinase levels or other adverse effects compared with placebo. Statins exerted no effect on growth or sexual development.

Conclusion

Statins are quite effective in reducing TC, LDL-C, TG and apo-B and increasing HDL-C concentrations in children and adolescents with FH. No safety issues were seen with statin use.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat A. Wiegman, S.S. Gidding, G.F. Watts, M.J. Chapman, H.N. Ginsberg, M. Cuchel, L. Ose, M. Averna, C. Boileau, J. Boren, E. Bruckert, A.L. Catapano, J.C. Defesche, O.S. Descamps, R.A. Hegele, G.K. Hovingh, S.E. Humphries, P.T. Kovanen, J.A. Kuivenhoven, L. Masana, B.G. Nordestgaard, P. Pajukanta, K.G. Parhofer, F.J. Raal, K.K. Ray, R.D. Santos, A.F. Stalenhoef, E. Steinhagen-Thiessen, E.S. Stroes, M.R. Taskinen, A. Tybjaerg-Hansen, O. Wiklund, Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur. Heart J. 36(36), 2425–2437 (2015). https://​doi.​org/​10.​1093/​eurheartj/​ehv157 CrossRefPubMedPubMedCentral A. Wiegman, S.S. Gidding, G.F. Watts, M.J. Chapman, H.N. Ginsberg, M. Cuchel, L. Ose, M. Averna, C. Boileau, J. Boren, E. Bruckert, A.L. Catapano, J.C. Defesche, O.S. Descamps, R.A. Hegele, G.K. Hovingh, S.E. Humphries, P.T. Kovanen, J.A. Kuivenhoven, L. Masana, B.G. Nordestgaard, P. Pajukanta, K.G. Parhofer, F.J. Raal, K.K. Ray, R.D. Santos, A.F. Stalenhoef, E. Steinhagen-Thiessen, E.S. Stroes, M.R. Taskinen, A. Tybjaerg-Hansen, O. Wiklund, Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur. Heart J. 36(36), 2425–2437 (2015). https://​doi.​org/​10.​1093/​eurheartj/​ehv157 CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat B.G. Nordestgaard, M.J. Chapman, S.E. Humphries, H.N. Ginsberg, L. Masana, O.S. Descamps, O. Wiklund, R.A. Hegele, F.J. Raal, J.C. Defesche, A. Wiegman, R.D. Santos, G.F. Watts, K.G. Parhofer, G.K. Hovingh, P.T. Kovanen, C. Boileau, M. Averna, J. Boren, E. Bruckert, A.L. Catapano, J.A. Kuivenhoven, P. Pajukanta, K. Ray, A.F. Stalenhoef, E. Stroes, M.R. Taskinen, A. Tybjaerg-Hansen, Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 34(45), 3478–3490a (2013). https://​doi.​org/​10.​1093/​eurheartj/​eht273 CrossRefPubMedPubMedCentral B.G. Nordestgaard, M.J. Chapman, S.E. Humphries, H.N. Ginsberg, L. Masana, O.S. Descamps, O. Wiklund, R.A. Hegele, F.J. Raal, J.C. Defesche, A. Wiegman, R.D. Santos, G.F. Watts, K.G. Parhofer, G.K. Hovingh, P.T. Kovanen, C. Boileau, M. Averna, J. Boren, E. Bruckert, A.L. Catapano, J.A. Kuivenhoven, P. Pajukanta, K. Ray, A.F. Stalenhoef, E. Stroes, M.R. Taskinen, A. Tybjaerg-Hansen, Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 34(45), 3478–3490a (2013). https://​doi.​org/​10.​1093/​eurheartj/​eht273 CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat F. Mach, C. Baigent, A.L. Catapano, K.C. Koskinas, M. Casula, L. Badimon, M.J. Chapman, G.G. De Backer, V. Delgado, B.A. Ference, I.M. Graham, A. Halliday, U. Landmesser, B. Mihaylova, T.R. Pedersen, G. Riccardi, D.J. Richter, M.S. Sabatine, M.R. Taskinen, L. Tokgozoglu, O. Wiklund; Group, E.S.C.S.D., 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41(1), 111–188 (2020). https://​doi.​org/​10.​1093/​eurheartj/​ehz455 CrossRefPubMed F. Mach, C. Baigent, A.L. Catapano, K.C. Koskinas, M. Casula, L. Badimon, M.J. Chapman, G.G. De Backer, V. Delgado, B.A. Ference, I.M. Graham, A. Halliday, U. Landmesser, B. Mihaylova, T.R. Pedersen, G. Riccardi, D.J. Richter, M.S. Sabatine, M.R. Taskinen, L. Tokgozoglu, O. Wiklund; Group, E.S.C.S.D., 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41(1), 111–188 (2020). https://​doi.​org/​10.​1093/​eurheartj/​ehz455 CrossRefPubMed
11.
Zurück zum Zitat Programme, W.H.O.H.G.: Familial hypercholesterolaemia (FH): report of a second WHO consultation, Geneva, 4 September 1998. In., vol. WHO/HGN/FH/CONS/99.2. World Health Organization, Geneva, (1999) Programme, W.H.O.H.G.: Familial hypercholesterolaemia (FH): report of a second WHO consultation, Geneva, 4 September 1998. In., vol. WHO/HGN/FH/CONS/99.2. World Health Organization, Geneva, (1999)
14.
Zurück zum Zitat Representatives of the Global Familial Hypercholesterolemia, C. Wilemon, K.A. Patel, J. Aguilar-Salinas, C. Ahmed, C.D. Alkhnifsawi, M. Almahmeed, W. Alonso, R. Al-Rasadi, K. Badimon, L. Bernal, L.M. Bogsrud, M.P. Braun, L.T. Brunham, L. Catapano, A.L. Cillíková, K. Corral, P. Cuevas, R. Defesche, J.C. Descamps, O.S. de Ferranti, S. Eiselé, J.-L. Elikir, G. Folco, E. Freiberger, T. Fuggetta, F. Gaspar, I.M. Gesztes, Á.G. Grošelj, U. Hamilton-Craig, I. Hanauer-Mader, G. Harada-Shiba, M. Hastings, G. Hovingh, G.K. Izar, M.C. Jamison, A. Karlsson, G.N. Kayikçioglu, M. Koob, S. Koseki, M. Lane, S. Lima-Martinez, M.M. López, G. Martinez, T.L. Marais, D. Marion, L. Mata, P. Maurina, I. Maxwell, D. Mehta, R. Mensah, G.A. Miserez, A.R. Neely, D. Nicholls, S.J. Nohara, A. Nordestgaard, B.G. Ose, L. Pallidis, A. Pang, J. Payne, J. Peterson, A.L. Popescu, M.P. Puri, R. Ray, K.K. Reda, A. Sampietro, T. Santos, R.D. Schalkers, I. Schreier, L. Shapiro, M.D. Sijbrands, E. Soffer, D. Stefanutti, C. Stoll, M. Sy, R.G. Tamayo, M.L. Tilney, M.K. Tokgözoglu, L. Tomlinson, B. Vallejo-Vaz, A.J. Vazquez-Cárdenas, A. de Luca, P.V. Wald, D.S. Watts, G.F. Wenger, N.K. Wolf, M. Wood, D. Zegerius, A. Gaziano, T.A. Gidding, S.S.: Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action. JAMA Cardiol. https://​doi.​org/​10.​1001/​jamacardio.​2019.​5173 (2020) Representatives of the Global Familial Hypercholesterolemia, C. Wilemon, K.A. Patel, J. Aguilar-Salinas, C. Ahmed, C.D. Alkhnifsawi, M. Almahmeed, W. Alonso, R. Al-Rasadi, K. Badimon, L. Bernal, L.M. Bogsrud, M.P. Braun, L.T. Brunham, L. Catapano, A.L. Cillíková, K. Corral, P. Cuevas, R. Defesche, J.C. Descamps, O.S. de Ferranti, S. Eiselé, J.-L. Elikir, G. Folco, E. Freiberger, T. Fuggetta, F. Gaspar, I.M. Gesztes, Á.G. Grošelj, U. Hamilton-Craig, I. Hanauer-Mader, G. Harada-Shiba, M. Hastings, G. Hovingh, G.K. Izar, M.C. Jamison, A. Karlsson, G.N. Kayikçioglu, M. Koob, S. Koseki, M. Lane, S. Lima-Martinez, M.M. López, G. Martinez, T.L. Marais, D. Marion, L. Mata, P. Maurina, I. Maxwell, D. Mehta, R. Mensah, G.A. Miserez, A.R. Neely, D. Nicholls, S.J. Nohara, A. Nordestgaard, B.G. Ose, L. Pallidis, A. Pang, J. Payne, J. Peterson, A.L. Popescu, M.P. Puri, R. Ray, K.K. Reda, A. Sampietro, T. Santos, R.D. Schalkers, I. Schreier, L. Shapiro, M.D. Sijbrands, E. Soffer, D. Stefanutti, C. Stoll, M. Sy, R.G. Tamayo, M.L. Tilney, M.K. Tokgözoglu, L. Tomlinson, B. Vallejo-Vaz, A.J. Vazquez-Cárdenas, A. de Luca, P.V. Wald, D.S. Watts, G.F. Wenger, N.K. Wolf, M. Wood, D. Zegerius, A. Gaziano, T.A. Gidding, S.S.: Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action. JAMA Cardiol. https://​doi.​org/​10.​1001/​jamacardio.​2019.​5173 (2020)
17.
Zurück zum Zitat P. Couture, L.D. Brun, F. Szots, M. Lelievre, D. Gaudet, J.P. Despres, J. Simard, P.J. Lupien, C. Gagne, Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 18(6), 1007–1012 (1998) CrossRefPubMed P. Couture, L.D. Brun, F. Szots, M. Lelievre, D. Gaudet, J.P. Despres, J. Simard, P.J. Lupien, C. Gagne, Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 18(6), 1007–1012 (1998) CrossRefPubMed
18.
Zurück zum Zitat E.A. Stein, D.R. Illingworth, P.O. Kwiterovich Jr., C.A. Liacouras, M.A. Siimes, M.S. Jacobson, T.G. Brewster, P. Hopkins, M. Davidson, K. Graham, F. Arensman, R.H. Knopp, C. DuJovne, C.L. Williams, J.L. Isaacsohn, C.A. Jacobsen, P.M. Laskarzewski, S. Ames, G.J. Gormley, Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 281(2), 137–144 (1999). https://​doi.​org/​10.​1001/​jama.​281.​2.​137 CrossRefPubMed E.A. Stein, D.R. Illingworth, P.O. Kwiterovich Jr., C.A. Liacouras, M.A. Siimes, M.S. Jacobson, T.G. Brewster, P. Hopkins, M. Davidson, K. Graham, F. Arensman, R.H. Knopp, C. DuJovne, C.L. Williams, J.L. Isaacsohn, C.A. Jacobsen, P.M. Laskarzewski, S. Ames, G.J. Gormley, Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 281(2), 137–144 (1999). https://​doi.​org/​10.​1001/​jama.​281.​2.​137 CrossRefPubMed
19.
Zurück zum Zitat S. de Jongh, L. Ose, T. Szamosi, C. Gagne, M. Lambert, R. Scott, P. Perron, D. Dobbelaere, M. Saborio, M.B. Tuohy, M. Stepanavage, A. Sapre, B. Gumbiner, M. Mercuri, A.S. van Trotsenburg, H.D. Bakker, J.J. Kastelein, Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 106(17), 2231–2237 (2002). https://​doi.​org/​10.​1161/​01.​cir.​0000035247.​42888.​82 CrossRefPubMed S. de Jongh, L. Ose, T. Szamosi, C. Gagne, M. Lambert, R. Scott, P. Perron, D. Dobbelaere, M. Saborio, M.B. Tuohy, M. Stepanavage, A. Sapre, B. Gumbiner, M. Mercuri, A.S. van Trotsenburg, H.D. Bakker, J.J. Kastelein, Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 106(17), 2231–2237 (2002). https://​doi.​org/​10.​1161/​01.​cir.​0000035247.​42888.​82 CrossRefPubMed
27.
Zurück zum Zitat V.G. Athyros, K. Tziomalos, T.D. Gossios, T. Griva, P. Anagnostis, K. Kargiotis, E.D. Pagourelias, E. Theocharidou, A. Karagiannis, D.P. Mikhailidis, Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 376(9756), 1916–1922 (2010). https://​doi.​org/​10.​1016/​s0140-6736(10)61272-x CrossRefPubMed V.G. Athyros, K. Tziomalos, T.D. Gossios, T. Griva, P. Anagnostis, K. Kargiotis, E.D. Pagourelias, E. Theocharidou, A. Karagiannis, D.P. Mikhailidis, Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 376(9756), 1916–1922 (2010). https://​doi.​org/​10.​1016/​s0140-6736(10)61272-x CrossRefPubMed
30.
Zurück zum Zitat N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A.J. de Craen, S.R. Seshasai, J.J. McMurray, D.J. Freeman, J.W. Jukema, P.W. Macfarlane, C.J. Packard, D.J. Stott, R.G. Westendorp, J. Shepherd, B.R. Davis, S.L. Pressel, R. Marchioli, R.M. Marfisi, A.P. Maggioni, L. Tavazzi, G. Tognoni, J. Kjekshus, T.R. Pedersen, T.J. Cook, A.M. Gotto, M.B. Clearfield, J.R. Downs, H. Nakamura, Y. Ohashi, K. Mizuno, K.K. Ray, I. Ford, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716), 735–742 (2010). https://​doi.​org/​10.​1016/​S0140-6736(09)61965-6 CrossRefPubMed N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A.J. de Craen, S.R. Seshasai, J.J. McMurray, D.J. Freeman, J.W. Jukema, P.W. Macfarlane, C.J. Packard, D.J. Stott, R.G. Westendorp, J. Shepherd, B.R. Davis, S.L. Pressel, R. Marchioli, R.M. Marfisi, A.P. Maggioni, L. Tavazzi, G. Tognoni, J. Kjekshus, T.R. Pedersen, T.J. Cook, A.M. Gotto, M.B. Clearfield, J.R. Downs, H. Nakamura, Y. Ohashi, K. Mizuno, K.K. Ray, I. Ford, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716), 735–742 (2010). https://​doi.​org/​10.​1016/​S0140-6736(09)61965-6 CrossRefPubMed
39.
Zurück zum Zitat M. Braamskamp, G. Langslet, B.W. McCrindle, D. Cassiman, G.A. Francis, C. Gagne, D. Gaudet, K.M. Morrison, A. Wiegman, T. Turner, E. Miller, D.M. Kusters, J.S. Raichlen, P.D. Martin, E.A. Stein, J.J.P. Kastelein, B.A. Hutten, Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the CHARON study (hypercholesterolemia in children and adolescents taking rosuvastatin open label). Circulation 136(4), 359–366 (2017). https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​116.​025158 CrossRefPubMed M. Braamskamp, G. Langslet, B.W. McCrindle, D. Cassiman, G.A. Francis, C. Gagne, D. Gaudet, K.M. Morrison, A. Wiegman, T. Turner, E. Miller, D.M. Kusters, J.S. Raichlen, P.D. Martin, E.A. Stein, J.J.P. Kastelein, B.A. Hutten, Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the CHARON study (hypercholesterolemia in children and adolescents taking rosuvastatin open label). Circulation 136(4), 359–366 (2017). https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​116.​025158 CrossRefPubMed
Metadaten
Titel
Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials
verfasst von
Panagiotis Anagnostis
Konstantina Vaitsi
Panagiota Kleitsioti
Chrysanthi Mantsiou
Konstantinos Pavlogiannis
Vasilios G. Athyros
Dimitri P. Mikhailidis
Dimitrios G. Goulis
Publikationsdatum
24.04.2020
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2020
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02302-8

Weitere Artikel der Ausgabe 2/2020

Endocrine 2/2020 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.